Preferences help
enabled [disable] Abstract
Number of results
2012 | 5 | 19-39
Article title

Cyklooksygenaza-2 i jej rola w kancerogenezie

  • Uniwersytet Medyczny w Lublinie
  • Uniwersytet Medyczny w Lublinie
  • Uniwersytet Medyczny w Lublinie
  • Uniwersytet Medyczny w Lublinie
  • Uniwersytet Medyczny w Lublinie
  • Chandrasekharan N. V., Simmons D. L., The cyclooxygenases, „Genome Biology” 2004, nr 5 (9), s. 241.
  • Burdan F., Chalas A., Szumilo J., Cyclooxygenase and prostanoids-biological implications, „Postępy Higieny i Medycyny Doświadczalnej” (Online) 2006, nr 60, s. 129–141.
  • Cathcart M. C., O’Byrne K. J., Reynolds J. V., O’Sullivan J., Pidgeon G. P., COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention, “Biochimica et Biophysica Acta” 2012, nr 1825 (1), s. 49–63.
  • Williams C. S., DuBois R. N., Prostaglandin endoperoxide synthase: why two isoforms?, „American Journal of Physiology” 1996, nr 270 (3 Pt 1), s. 393–400.
  • Kargman S., Charleson S., Cartwright M., Frank J., Riendeau D., Mancini J., Evans J., O’Neill G., Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts, „Gastroenterology” 1996, nr 111 (2), s. 445–454.
  • Chandrasekharan N. V., Dai H., Roos K. L., Evanson N. K., Tomsik J., Elton T. S., Simmons D. L., COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression, „Proceedings of the National Academy of Science of the USA” 2002, nr 99 (21), s. 13926–13931.
  • Schwab J. M., Schluesener H. J., Meyermann R., Serhan C. N., COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?, „Prostaglandins Leukotrienes and Essential Fatty Acids” 2003, nr 69 (5), s. 339–343.
  • Sadurska B., Szumilo M., Phospholipases A in mammalian cells: structure, properties, physiological and pathological role, „Postępy Higieny i Medycyny Doświadczalnej” 2005, nr 59, s. 116–123.
  • Crofford L. J., Wilder R. L., Ristimaki A. P., Sano H., Remmers E. F., Epps H. R., Hla T., Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin- 1 beta, phorbol ester, and corticosteroids, „Journal of Clinical Investigation” 1994, nr 93 (3), s. 1095–1101.
  • Williams C. S., Mann M., DuBois R. N., The role of cyclooxygenases in inflammation, cancer, and development, „Oncogene” 1999, nr 18 (55), s. 7908–7916.
  • Soslow R. A., Dannenberg A. J., Rush D., Woerner B. M., Khan K. N., Masferrer J., Koki A. T., COX-2 is expressed in human pulmonary, colonic, and mammary tumors, „Cancer” 2000, nr 89 (12), s. 2637–2645.
  • Appleby S. B., Ristimaki A., Neilson K., Narko K., Hla T., Structure of the human cyclooxygenase- 2 gene, „Biochemical Journal” 1994, nr 302 (Pt 3), s. 723–727
  • Ristimaki A., Garfinkel S., Wessendorf J., Maciag T., Hla T., Induction of cyclooxygenase- 2 by interleukin-1 alpha. Evidence for post-transcriptional regulation, „The Journal of Biological Chemistry” 1994, nr 269 (16), s. 11769–11775.
  • Chan G., Boyle J. O., Yang E. K., Zhang F., Sacks P. G., Shah J. P., Edelstein D., Soslow R. A., Koki A. T., Woerner B. M., Masferrer J. L., Dannenberg A. J., Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck, „Cancer Research” 1999, nr 59 (5), nr 991–994.
  • van Rees B. P., Saukkonen K., Ristimaki A., Polkowski W., Tytgat G. N., Drillenburg P., Offerhaus G. J., Cyclooxygenase-2 expression during carcinogenesis in the human stomach, „Journal of Pathology” 2002, nr 196 (2), s. 171–179.
  • Souza R. F., Shewmake K., Beer D. G., Cryer B., Spechler S. J., Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells, „Cancer Research” 2000, nr 60 (20), s. 5767–5772.
  • Ristimaki A., Nieminen O., Saukkonen K., Hotakainen K., Nordling S., Haglund C., Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder, „American Journal of Pathology” 2001, nr 158 (3), s. 849–853.
  • Saukkonen K., Nieminen O., van Rees B., Vilkki S., Harkonen M., Juhola M., Mecklin J. P., Sipponen P., Ristimaki A., Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma, „Clinical Cancer Research” 2001, nr 7 (7), s. 1923–1931.
  • Simmons D. L., Botting R. M., Hla T., Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition, „Pharmacological Reviews” 2004, nr 56 (3), s. 387–437.
  • Snipes J. A., Kis B., Shelness G. S., Hewett J. A., Busija D. W., Cloning and characterization of cyclooxygenase-1b (putative cyclooxygenase-3) in rat, „Journal of Pharmacology and Experimental Therapeutics” 2005, nr 313 (2), s. 668–676.
  • Leahy K. M., Koki A. T., Masferrer J. L., Role of cyclooxygenases in angiogenesis, „Current Medical Chemistry” 2000, nr 7 (11), s. 1163–1170.
  • Krysan K., Dalwadi H., Sharma S., Pold M., Dubinett S., Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer, „Cancer Research” 2004, nr 64 (18), s. 6359–6362.
  • Baeriswyl V., Christofori G., The angiogenic switch in carcinogenesis, „Seminars in Cancer Biology” 2009, nr 19 (5), s. 329–337.
  • Richardson M. R., Yoder M. C., Endothelial progenitor cells: quo vadis?, „Journal of Molecular and Cellular Cardiology” 2011, nr 50 (2), s. 266–272.
  • Dome B., Hendrix M. J., Paku S., Tovari J., Timar J., Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications, „American Journal of Pathology” 2007, nr 170 (1), s. 1–15.
  • Chung A. S., Lee J., Ferrara N., Targeting the tumour vasculature: insights from physiological angiogenesis, „Nature Reviews Cancer”, nr 10 (7), s. 505–514.
  • Raza A., Franklin M. J., Dudek A. Z., Pericytes and vessel maturation during tumor angiogenesis and metastasis, „American Journal of Hemathology” 2010, nr 85 (8), s. 593–598.
  • Lee J. W., Bae S. H., Jeong J. W., Kim S. H., Kim K. W., Hypoxia-inducible factor (HIF-1) alpha: its protein stability and biological functions, „Expererimenatl and Mollecular Medicine” 2004, nr 36 (1), s. 1–12.
  • Gordan J. D., Simon M. C., Hypoxia-inducible factors: central regulators of the tumor phenotype, „Current Opinion in Genetics & Development” 2007, nr 17 (1), s. 71–77.
  • Masferrer J. L., Leahy K. M., Koki A. T., Zweifel B. S., Settle S. L., Woerner B. M., Edwards D. A., Flickinger A. G., Moore R. J., Seibert K., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, „Cancer Research” 2000, nr 60 (5), s. 1306– 1311.
  • Toomey D. P., Murphy J. F., Conlon K. C., COX-2, VEGF and tumour angiogenesis, „Surgeon” 2009, nr 7 (3), s. 174–180.
  • Schwab J. M., Schluesener H. J., Laufer S., COX-3: just another COX or the solitary elusive target of paracetamol?, „Lancet” 2003, nr 361 (9362), s. 981–982.
  • Salvado M. D., Alfranca A., Haeggstrom J. Z., Redondo J. M., Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2, „Trends in Molecular Medicine”, nr 18 (4), s. 233–243
  • Liu M., Yang S. C., Sharma S., Luo J., Cui X., Peebles K. A., Huang M., Sato M., Ramirez R. D., Shay J. W., Minna J. D., Dubinett S. M., EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells, „American Journal of Respiratory Cell and Molecular Biology” 2007, nr 37 (5), s. 578–588.
  • Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N., Cyclooxygenase regulates angiogenesis induced by colon cancer cells, Cell 1998, nr 93(5), s. 705–716.
  • Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis, Cancer Cell 2009, nr 15 (3), s. 220-231.
  • Ebos J. M., Kerbel R. S., Antiangiogenic therapy: impact on invasion, disease progression, and metastasis, „Nature Reviews Clinical Oncology” 2011, 8 (4), s. 210–221.
  • Widel M. S., Widel M., Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer, „Postępy Higieny i Medycyny Doświadczalnej” 2006, nr 60, s. 453–470.
  • Nagase H., Woessner J. F. Jr, Matrix metalloproteinases, „The Journal of Biological Chemistry” 1999, nr 274 (31), s. 21491–21494.
  • Somiari S. B., Shriver C. D., Heckman C., Olsen C., Hu H., Jordan R., Arciero C., Russell S., Garguilo G., Hooke J., Somiari R. I., Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer, „Cancer Letters” 2006, nr 233 (1), s. 98–107.
  • Bartolazzi A., Peach R., Aruffo A., Stamenkovic I., Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development, „Journal of Experimental Medicine” 1994, nr 180 (1), s. 53–66.
  • Misra S., Obeid L. M., Hannun Y. A., Minamisawa S., Berger F. G., Markwald R. R., Toole B. P., Ghatak S., Hyaluronan constitutively regulates activation of COX-2-mediated cell survival activity in intestinal epithelial and colon carcinoma cells, „The Journal of Biological Chemistry” 2008; nr 283 (21), s. 14335–14344.
  • Misra S., Hascall V. C., Berger F. G., Markwald R. R., Ghatak S., Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer, „Connective Tissue Research” 2008, nr 49 (3), s. 219–224.
  • Sitarz R., Leguit R. J., de Leng W. W., Morsink F. H., Polkowski W. P., Maciejewski R., Offerhaus G. J., Milne A. N., Cyclooxygenase-2 mediated regulation of E-cadherin occurs in conventional but not early-onset gastric cancer cell lines, „Cellular Oncology” 2009, nr 31 (6), s. 475–485.
  • Dohadwala M., Yang S. C., Luo J., Sharma S., Batra R. K., Huang M., Lin Y., Goodglick L., Krysan K., Fishbein M. C., Hong L., Lai C., Cameron R. B., Gemmill R. M., Drabkin H. A., Dubinett S.M., Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer, „Cancer Research” 2006, nr 66 (10), s. 5338–5345.
  • Huang M., Stolina M., Sharma S., Mao J. T., Zhu L., Miller P. W., Wollman J., Herschman H., Dubinett S. M., Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production, „Cancer Research” 1998, nr 58 (6), s. 1208–1216.
  • Colombo M. P., Vagliani M., Spreafico F., Parenza M., Chiodoni C., Melani C., Stoppacciaro A. Amount of interleukin 12 available at the tumor site is critical for tumor regression, „Cancer Research” 1996, s. 56 (11), s. 2531–2534.
  • Ristimaki A., Honkanen N., Jankala H., Sipponen P., Harkonen M., Expression of cyclooxygenase- 2 in human gastric carcinoma, „Cancer Research” 1997, nr 57 (7), s. 1276– 1280.
  • Wong S.C., Fukuchi M., Melnyk P., Rodger I., Giaid A., Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure, Circulation 1998, nr 98 (2), s. 100–103.
  • Milne A. N., Carvalho R., Morsink F. M., Musler A. R., de Leng W. W., Ristimaki A., Offerhaus G. J., Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers, „Modern Pathology” 2006, nr 19 (4), s. 564–572.
  • Sitarz R., Leguit R. J., de Leng W. W., Polak M., Morsink F. M., Bakker O., Maciejewski R., Offerhaus G. J., Milne A. N., The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers, „Modern Pathology” 2008, nr 21 (6), s. 685–690.
  • Tucker O. N., Dannenberg A. J., Yang E. K., Zhang F., Teng L., Daly J. M., Soslow R. A., Masferrer J. L., Woerner B. M., Koki A. T., Fahey T. J. 3rd, Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer, „Cancer Research” 1999, nr 59 (5), s. 987–990.
  • Catella-Lawson F., Reilly M. P., Kapoor S. C., Cucchiara A. J., DeMarco S., Tournier B., Vyas S. N., Fitzgerald G. A., Cyclooxygenase inhibitors and the antiplatelet effects of aspirin, „New England Journal of Medicine” 2001, nr 345 (25), s. 1809–1817.
  • Cheng H. F., Harris R. C., Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors, „Current Pharmaceutical Design” 2005, nr 11 (14), s. 1795–1804.
  • Espey L. L., Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction, „Biology of Reproduction” 1994, nr 50 (2), s. 233–238.
  • Salhab A. S., Gharaibeh M. N., Shomaf M. S., Amro B. I., Meloxicam inhibits rabbit ovulation, „Contraception” 2001, nr 63 (6), s. 329–333.
  • Yamagata K., Andreasson K. I., Kaufmann W. E., Barnes C. A., Worley P. F., Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids, „Neuron” 1993, nr 11 (2), s. 371–386. Young J. L., Jazaeri A. A., Darus C. J., Modesitt S. C., Cyclooxygenase-2 in cervical neoplasia: a review, „Gynecologic Oncology” 2008, nr 109 (1), s. 140–145.
  • Zha S., Yegnasubramanian V., Nelson W. G., Isaacs W. B., De Marzo A. M., Cyclooxygenases in cancer: progress and perspective, „Cancer Letters” 2004, nr 215 (1), s. 1–20.
  • Noordhuis M. G., Eijsink J. J., Roossink F., de Graeff P., Pras E., Schuuring E., Wisman G. B., de Bock G. H., van der Zee A. G., Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review, „International Journal of Radiation Oncology*Biology*Physics” 2011, nr 79 (2), s. 325–334.
  • Mascaux C., Martin B., Verdebout J. M., Ninane V., Sculier J. P., COX-2 expression during early lung squamous cell carcinoma oncogenesis, „European Respiratory Journal” 2005, nr 26 (2), s. 198–203.
  • Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., Ogawa M., Mitsudomi T., Sugiura T., Takahashi T., Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas, „Cancer Research” 1998, nr 58 (17), s. 3761–3764.
  • Yuan A., Yu C. J., Shun C. T., Luh K. T., Kuo S. H., Lee Y. C., Yang P. C., Total cyclooxygenase- 2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients, „International Journal of Cancer” 2005, nr 115 (4), s. 545–555.
  • Jones R., Rubin G., Berenbaum F., Scheiman J., Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs, „American Journal of Medicine” 2008, nr 121 (6), s. 464–474.
  • Wang W. H., Huang J. Q., Zheng G. F., Lam S. K., Karlberg J., Wong B. C., Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and metaanalysis, „Journal of the National Cancer Institute” 2003, nr 95 (23), s. 1784–1791.
  • Hull M. A., Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?, „European Journal of Cancer” 2005, nr 41 (13), s. 1854–1863.
  • Grimes K. R., Warren G. W., Fang F., Xu Y., St. Clair W. H., Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo, „Oncology Reports” 2006, nr 16 (4), s. 771–776.
  • Bundred N. J., Barnes N. L., Potential use of COX-2-aromatase inhibitor combinations in breast cancer, „British Journal of Cancer” 2005, nr 93, Suppl. 1: s. 10–15.
  • Lasalvia-Prisco E., Goldschmidt P., Galmarini F., Cucchi S., Vazquez J., Aghazarian M., Lasalvia-Galante E., Golomar W., Gordon W., Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies, „Medical Oncology” 2012, nr 29 (5), s. 3626–3633.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.